# IgGenix
*Also known as IgGenix*

- Website: https://www.derekcroote.com
- Agent profile: https://nowen.ai/agents/derekcroote-com
- Industry: Biotechnology

> IgGenix is a clinical-stage biotech company developing antibody therapies to treat allergies.

IgGenix is a clinical-stage biotechnology company focused on discovering and developing antibody-based therapies to treat allergies. Led by experienced biotech leaders, the company seeks to translate scientific research into transformative treatments that improve the health and well-being of individuals affected by allergic conditions. IgGenix emphasizes scientific rigor, collaboration, and patient impact as it advances its internal programs through clinical development.

**Mission:** IgGenix's mission is to develop transformational antibody therapies that improve the health and quality of life for people living with allergies.

## Products & Services

### [IGNX001](https://iggenix.com/pressreleases/iggenix-announces-first-patient-dosed-in-phase-1-clinical-trial-accelerate-peanut-evaluating-ignx001-in-peanut-allergy/)
*Product*
Transformative antibody therapeutic for peanut allergy, completed Phase 1 trial.

- **Phase 1 completion** — Achieved Phase 1 Clinical Trial

## Market Segments

- **Peanut allergy therapeutics** (market size $1.1B, CAGR 16.9%): Therapies specifically designed to prevent or reduce allergic reactions to peanuts, including monoclonal antibodies and targeted immunotherapies aimed at desensitization and protection from anaphylaxis.
- **Clinical-stage antibody therapeutics** (market size $311.2B, CAGR 7.5%): Monoclonal antibody candidates undergoing clinical development for immune-mediated conditions, with emphasis on clinical safety, efficacy, and advancement through Phase 1–3 trials.
- **Biopharmaceutical partnering and licensing** (market size $15.0B, CAGR 9%): Opportunities for licensing, co-development, and strategic partnerships around clinical-stage biologic assets to accelerate development, manufacturing, and commercialization.